• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech Product Image

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech

  • Published: February 2014
  • Region: Global
  • 4436 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Boehringer Ingelheim
  • Facet Biotechnology
  • Kyowa Hakko Kirin
  • Morphosys
  • RIT Oncology
  • MORE

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 4,000 links to online copies of actual discovery stage deals and contract documents as submitted to READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Why do companies partner at discovery stage?
2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 – Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Pfizer - Repligen
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Roche – Genentech - Chiasma
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Coley Pharmaceutical – Dynavax Technologies
3.6.1.b. Case study : Novartis – Marina Biotech
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon –Boehringer Ingelheim – Macrogenics
3.7.1.b. Case study: Fibrocell Science – Intrexon

Chapter 4 – Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 – Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1.. Attributes of discovery deals
5.3. Big pharma discovery stage dealmaking activity
5.4. Big biotech discovery stage dealmaking activity
5.5. Discovery stage partnering by deal type
5.6. Discovery stage partnering by disease type
5.7. Discovery stage partnering by technology type

Chapter 6 – Average payment terms for discovery stage partnering
6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
Figure 17: Discovery stage deals with a headline value- 2009
Figure 18: Discovery stage deals with a headline value- 2010
Figure 19: Discovery stage deals with a headline value- 2011
Figure 20: Discovery stage deals with a headline value- 2012
Figure 21: Discovery stage deals with a headline value- 2013
6.4.2. Discovery stage upfront payments
Figure 24: Discovery stage deals with upfront payment values- 2009
Figure 25: Discovery stage deals with upfront payment values– 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
6.4.3. Discovery stage milestone payments
Figure 31: Discovery stage deals with milestone payments -2009
Figure 32: Discovery stage deals with milestone payments -2010
Figure 33: Discovery stage deals with milestone payments -2011
Figure 34: Discovery stage deals with milestone payments -2012
Figure 35: Discovery stage deals with milestone payments -2013
6.4.4. Discovery stage royalty rates
Figure 38: Discovery stage deals with royalty rates, %- 2009
Figure 39: Discovery stage deals with royalty rates, %- 2010
Figure 40: Discovery stage deals with royalty rates, %- 2011
Figure 41: Discovery stage deals with royalty rates, %- 2012
Figure 42: Discovery stage deals with royalty rates, %- 2013

Chapter 7 – Leading preclinical stage deals
7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 – Big pharma and big biotech discovery stage partnering deals
8.1. Introduction
8.2. How to use big pharma/big biotech discovery stage partnering deals
8.3. Big pharma discovery stage partnering company profiles
Abbott
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Animal Health
Bayer CropScience
Bayer Healthcare
Bayer Innovation
Bayer Schering Pharma
Bayer Technology Services
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
CSL Biotherapies
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eisai Inc
Eli Lilly
Endo Pharmaceuticals
Fresenius
Fresenius Kabi Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson & Johnson
Johnson & Johnson Development Corporation
Johnson & Johnson Innovation
Johnson & Johnson Pharmaceutical Research Institute
Janssen-Cilag
Janssen Biotech
Janssen Pharmaceutica KK
Janssen Pharmaceutica NV
Janssen Pharmaceutical
Janssen Research & Development
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Novartis
Novartis Institute for Tropical Diseases
Novartis Molecular Diagnostics
Novartis Venture Funds
Novo Nordisk
Otsuka
Pfizer
Pfizer Animal Health
Roche
Roche Applied Science
Roche Diagnostics
Roche Institute for Research and Translational Medicine
Roche Molecular Systems
Roche NimbleGen
Genentech
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Servier
Shionogi
Shire
Shire Human Genetic Therapies
Takeda
Takeda Cambridge
Takeda San Francisco
Teva
UCB
Valeant
Warner Chilcott

8.4. Big biotech discovery stage partnering company profiles

3SBio
Actelion
Alexion Pharmaceuticals
Array Biopharma
Bavarian Nordic
Biocon
Cangene
Cubist
Dendreon
Elan
Emergent BioSolutions
Galapagos
Genmab
Ipsen
Isis Pharmaceuticals
Morphosys
Onyx Pharmaceuticals
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Seattle Genetics
United Therapeutics
Vertex Pharmaceuticals

Chapter 9 – Discovery stage partnering contracts directory

9.1. Introduction
9.2. Company A-Z
ABT Holding Company
ACADIA Pharmaceuticals
Adamis Pharmaceuticals
Adeona Pharmaceuticals
Adimab
Advanced Cell Technology
Advaxis
Advirna
Agensys
Aldagen
Alexion Pharmaceuticals
Alimera Sciences
Alnylam Pharmaceuticals
Altman Enterprises
Ambit Biosciences
America Stem Cell
American Type Culture Collection (ATCC)
Amgen
Anacor Pharmaceuticals
Angiotech Pharmaceuticals
Antigenics
Applied Genetic Technologies
Arana Therapeutics
Arno Therapeutics
ArQule
Array Biopharma
Arrayit Diagnostics
Astellas Pharma
AstraZeneca
Asubio Pharma
Athersys
Atlantic Healthcare
Avalon Pharmaceuticals
AVEO Pharmaceuticals
AVI Pharma
Bayer Schering Pharma
BG Medicine
BIND Biosciences
BIND Therapeutics
Bio-Matrix Scientific
Bio-Path
Biocurex
Biogen Idec
BioTime
Biovail
BioWa
BioZone Laboratories
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Bristol-Myers Squibb
Buck Institute for Age Research
Cadila Pharmaceuticals
Cardiff University
Cardium Therapeutics
Catalyst Pharmaceutical Partners
Cedars-Sinai Medical Center
Celera
Celgene
Celladon
Centocor Ortho Biotech
CHA Bio & Diostech
Charleys Fund
CHDI Foundation
Chi-Fu Trading
Children's Hospital Boston
Chiva Pharmaceuticals
Clinical Data
Codexis
Cohen-McNiece Foundation
Columbia University
CombinatoRx
CorMedix
CPL Biologicals
Crucell
Cystic Fibrosis Foundation
Cytokinetics
Cytori Therapeutics
CytRx
Daiichi Sankyo
Dana-Farber Cancer Institute
DARA BioSciences
DeCODE Genetics
Defense Threat Reduction Agency
Delcath Systems
Department of Homeland Security
Dharmacon
DNA Biomedical Solutions
Dow AgroSciences
Dynavax Technologies
Edison Pharmaceuticals
Elanco
Eleven Biotherapeutics
Eli Lilly
Embryome Sciences
Emory University
Enanta Pharmaceuticals
Enox BioPharma
Entera Bio
Entest BioMedical
Enzon Pharmaceuticals
EPIX Pharmaceuticals
Exact Sciences
Exelixis
Fate Therapeutics
Fibrocell Science
Fraunhofer USA
Fudan University
Galena Biopharma
GE Healthcare
Gen-Probe
Genentech
Genoptix
GenVec
Genzyme
Geron
GlaxoSmithKline
GlobeImmune
GlycArt
Health Discovery
Heat Biologics
Henry M. Jackson Foundation
IBioPharma
Icagen
Ilypsa
ImaRX
ImmunoCellular Therapeutics
ImmunoGen
Infinity Pharmaceuticals
Inhibitex
Intellect Neurosciences
Intellikine
Intercept Pharmaceuticals
InterMune
Intrexon
Invivis Pharmaceuticals
Iogen Energy
Isis Pharmaceuticals
Janssen Pharmaceutica NV
Johns Hopkins University
Johnson & Johnson
Kaketsuken
KaloBios Pharmaceuticals
Karyopharm Therapeutics
Kraig Biocraft Laboratories
Lankenau Institute for Medical Research
Lexicon Pharmaceuticals
Ligand Pharmaceuticals
Lonza
Macrogenics
Marina Biotech
Marv Enterprises
Massachusetts General Hospital
Maxygen
MD Anderson Cancer Center
Medi-Pharmaceuticals
Merck and Co
Merrimack Pharmaceuticals
Metabasis Therapeutics
Micromet
Millennium
Multiple Myeloma Research Foundation
Nanshan Memorial Medical Institute
National Institute of Allergy and Infectious Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Neogenomics
Neurobiological Technologies
Neurocrine Biosciences
New York University
Newlink Genetics
Nitricare
Nitto Denko
Northwestern University
Novartis
Novavax
Novo Nordisk
Ohio State University
Omeros
Omnimmune
Opexa Therapeutics
Oragenics
Oramed Pharmaceuticals
Organon
Organovo
Orphazyme
Ortho-McNeil
OSI Pharmaceuticals
Ottawa Hospital Research Institute
Oxygen Biotherapeutics
Pacific BioScience of California
Pacific Biosciences
Palatin Technologies
Penwest Pharmaceuticals
Peregrine Pharmaceuticals
Perseid Therapeutics
Perugia University
Pfizer
Pharmacopeia
Poniard Pharmaceuticals
Premier Biomedical
Pro Pharmaceuticals
Prometheus
Protein Polymer Technologies
Proteonomix
Psynova Neurotech
Public Health Service
Quark Pharmaceuticals
Ramot at Tel Aviv University
Regeneron Pharmaceuticals
Regulus Therapeutics
Relypsa
Reproductive Genetics Institute
Response Genetics
Rib-X Pharmaceuticals
Roche
Roquette
RTI Surgical
Rules-Based Medicine
RXi Pharmaceuticals
Sangamo BioSciences
Sanming Huajian Bioengineering
Sanofi-Aventis
Sanofi
Santaris
Sanyo
Schepens Eye Research Institute
Scripps Research Institute
Seattle Genetics
Servier
Shell Oil Company
Shell Oil Products
Shiva Biomedical
Sigma-Aldrich
Skyline Diagnostics
Solazyme-Roquette Nutritionals
Solazyme
Sorrento Therapeutics
Stanford University
Stemco Biomedical
SuperGen
Synthetic Blood International
Takeda Pharmaceutical
Targacept
Targeted Genetics
The Regents of the University of California
Therinject
ThermoGenesis
ThromboGenics
Transgenomic
Tranzyme Pharma
Trevena
Trius Therapeutics
TrovaGene
TTFactor
University of Cambridge
University of Colorado
University of Connecticut
University of Florida Research Foundation
University of Miami
University of Michigan
University of Minnesota
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Texas
University of Wuerzburg
Verastem
Verio Therapeutics
Virginia Commonwealth University
WA 32609
Wayne State University
Whitehead Institute
Wisconsin Alumni Research Foundation
Wyeth
Xencor
Xoma
Yale University
Zoetis
ZymoGenetics

9.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Sub-license
Supply
Technology transfer
Termination
Warranty

9.4. By stage of development

Discovery
Formulation
Phase I
Phase II
Preclinical

9.5. By therapy area

Cardiovascular
Angina
Atherosclerosis
Congestive heart failure
Central Nervous System
Epilepsy
Pain
Parkinson's disease
Stroke
Dermatology
Gastrointestinal
Ulcerative colitis
Genetic disorders
Cystic Fibrosis (CF)
Huntington's disease
Genitourinary
Renal failure
Gynaecology
Hematology
Anemia
Hospital care
Orthopedics
Transplantation
Immunology
Inflammation
Infectives
Bacterial
Methicillin-resistant Staphylococcus aureus (MRSA)
Viral
Foot and mouth disease
B

C
HIV
Influenza
H1N1 (Swine Flu)
Metabolic
Cirrhosis
Diabetes
Type 2
Liver disease
Lysosomal storage disorders
Musculoskeletal
Rheumatoid arthritis
Muscular dystrophy
Spinal muscular atrophy
Obstetrics
Oncology
Bladder cancer
Brain cancer
Breast cancer
Colorectal cancer
Head and neck cancer
Leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Liver cancer
Lung cancer
Lymphoma
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Solid tumors
Ophthalmics
Age-related macular degeneration
Blindness
Diabetic macular edema
Glaucoma
Retinopathy
Psychiatry
Attention deficit hyperactivity disorder
Cognitive impairment
Alzheimers
Schizophrenia
Public health
Addiction
Obesity
Respiratory
Asthma
Chronic obstructive pulmonary disease
Pulmonary arterial hypertension

Chapter 10 – Discovery stage dealmaking directory

10.1. Introduction
10.2. Deals by discovery stage

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Reports
Order Form – Therapy Reports

View the accompanying volume for:

Appendices

Introduction

Appendix 1 – Directory of discovery stage deals by company A-Z 2009-2013
Appendix 2 – Directory of discovery stage deals by deal type 2009-2013
Appendix 3 – Directory of discovery stage deals by therapy area 2009-2013
Appendix 4 – Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2009-2013), % of all deals where stage disclosed
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for discovery stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Discovery stage partnering frequency 2009-2013
Figure 7: Big pharma – top 50 – discovery stage deals 2009 to 2013
Figure 8: Big pharma discovery stage deal frequency – 2009 to 2013
Figure 9: Big biotech – top 50 – discovery stage deals 2009 to 2013
Figure 10: Big biotech discovery stage deal frequency – 2009 to 2013
Figure 11: Discovery stage partnering by deal type since 2009
Figure 12: Discovery stage partnering by disease type since 2009
Figure 13: Discovery stage partnering by technology type since 2009
Figure 14: Review of median upfront payments for discovery stage deals
Figure 15: Review of median milestone payments for discovery stage deals
Figure 16: Review of median royalty payments for discovery stage deals
Figure 17: Discovery stage deals with a headline value- 2009
Figure 18: Discovery stage deals with a headline value- 2010
Figure 19: Discovery stage deals with a headline value- 2011
Figure 20: Discovery stage deals with a headline value- 2012
Figure 21: Discovery stage deals with a headline value- 2013
Figure 22: Discovery stage deal headline value distribution, US$million
Figure 23: Summary median headline value for discovery stage of development, 2009-2013
Figure 24: Discovery stage deals with upfront payment values- 2009
Figure 25: Discovery stage deals with upfront payment values– 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deal upfront payment distribution, US$million
Figure 30: Summary median upfront payments discovery stage of development, 2009-2013
Figure 31: Discovery stage deals with milestone payments -2009
Figure 32: Discovery stage deals with milestone payments -2010
Figure 33: Discovery stage deals with milestone payments -2011
Figure 34: Discovery stage deals with milestone payments -2012
Figure 35: Discovery stage deals with milestone payments -2013
Figure 36: Discovery stage deal milestone distribution, US$million
Figure 37: Summary median milestone payments for discovery stage of development, 2009-2014
Figure 38: Discovery stage deals with royalty rates, %- 2009
Figure 39: Discovery stage deals with royalty rates, %- 2010
Figure 40: Discovery stage deals with royalty rates, %- 2011
Figure 41: Discovery stage deals with royalty rates, %- 2012
Figure 42: Discovery stage deals with royalty rates, %- 2013
Figure 43: Discovery stage deal royalty rate distribution, US$million
Figure 44: Summary median royalty rate for discovery stage of development, 2009-2013
Figure 45: Top discovery stage deals by value since 2009

Provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies

Benefits

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

- In-depth understanding of discovery stage deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of discovery stage agreements with numerous real life case studies
- Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a discovery stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Discovery Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech includes:
- Trends in discovery stage dealmaking in the biopharma industry since 2007
- Analysis of discovery stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life discovery stage deals
- Access to over 2,500 discovery stage deals
- The leading discovery stage deals by value since 2007
- Most active discovery stage dealmakers since 2007
- The leading discovery stage partnering resources

In Discovery Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Discovery Stage Partnering Terms and Agreements in Pharma and biotech report provides comprehensive access to available deals and contract documents for over 2,500 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Abbott
Actavis
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Fresenius Biotech
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Takeda
Teva
Alexion Pharmaceuticals
Elan
Emergent BioSolutions
Galapagos
Genmab
LFB Group
Morphosys
Novo Nordisk
PDL BioPharma
Regeneron Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
ADMA Biologics
Alexion Pharmaceuticals
Amgen
AstraZeneca
Avecia Biologics
AVEO Pharmaceuticals
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Centocor Ortho Biotech
Crucell
Cytodyn
Elan
Facet Biotechnology
GE Healthcare
Genzyme
GlycArt
Green Cross
ImmunoCellular Therapeutics
ImmunoGen
Intrexon
KaloBios Pharmaceuticals
Lonza
Lpath
Macrogenics
Massachusetts Biologic Laboratories
Medarex
Merrimack Pharmaceuticals
Micromet
Millennium
MorphoSys
Orbimed Advisors
Peregrine Pharmaceuticals
PharmAthene
Progenics Pharmaceuticals
Regeneron Pharmaceuticals
Repligen
RIT Oncology
Stason Pharmaceuticals
Synthetic Biologics
Targepeutics
TrovaGene
TTFactor
University of Texas
Wyeth
Xencor
Xoma
ZymoGenetics

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos